- Zonetail (ZONE) has signed two agreements for its mobile residential platform, which offers COVID-19 testing capabilities at home
- The agreements are with Avrok Laboratories and Ostia Sciences, companies which have partnered to offer COVID-19 surveillance screening
- Avrok’s Next Gen Sequencing technology is 99 per cent accurate and more cost-effective than other COVID-19 testing methods
- Users of Zonetail’s residential platform will be able to buy NGS screening kits through the app and have them delivered
- Zonetail is up 40.91 per cent and is currently trading for C$0.16 per share
Zonetail (ZONE) has signed two agreements for its mobile residential platform, which offers COVID-19 testing capabilities at home.
The company signed the agreements with Avrok Laboratories in Los Angeles, California and Ostia Sciences in Toronto, Ontario. These companies have partnered in Canada in order to offer COVID-19 surveillance screening services.
Avrok’s Next Gen Sequencing (NGS) technology is 99 per cent accurate at screening for SARS-CoV-2, and is more cost-effective than other COVID-19 testing methods.
The Infect No More service, which this screening is available through, uses Avrok’s oral sample collection system, which is a painless alternative to uncomfortable nasal swabs.
Users of Zonetail’s residential platform will be able to buy a NGS screening kit through the company’s app, and have the kit delivered directly to their door.
This service will be made available to all Zonetail-supported condominiums throughout Canada. Furthermore, once the company’s integration with Yardi is complete, the testing kits will also be available to condominiums and apartments in the United States.
Under the agreements, Zonetail will receive a fee for each test kit which is purchased through the company’s network.
Zonetail’s CEO, Mark Holmes, noted that even with vaccines now being rolled out, people will continue to need regular testing for the foreseeable future.
“Testing is important to get this pandemic under control, but many people don’t have the means to get to a public testing station. Even those that do, many don’t want to,” he said.
“They are afraid that even going to a public test site can put them at risk of catching the disease. This is a great and convenient way to address these issues,” he added.
Zonetail is up 40.91 per cent and trading for $0.16 per share, as of 10:43am EST.